Clinical trial · Interventional
Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm
Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm: a Prospective， Single-arm, Multi-center, Phase Ⅱ Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study investigated the efficacy and safety of a selective lymph node strategy (no lower mediastinal lymph node dissection for upper lobe tumors and no upper mediastinal lymph node dissection for lower lobe tumors) in patients with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter cT1N0M0 infiltrating NSCLC, aiming to more accurately assess the prognosis of the selective lymph node dissection strategy for nodes with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer (NSCLC) | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
| Lymph Node Dissection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Selective lymph node dissection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm Selective lymph node dissection
- description
- Lower mediastinal lymph node clearance is not required for upper lobe tumors and upper mediastinal lymph node clearance is not required for lower lobe tumors in the group
- interventionNames
- Procedure: Selective lymph node dissection
Primary outcomes (1)
- measure
- 2-year disease-free survival
- timeFrame
- From enrollment to the end of treatment at 2 years
Secondary outcomes (1)
- measure
- 2-year overall survival
- timeFrame
- From enrollment to the end of treatment at 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Volunteer to participate in a clinical study and be willing to follow and have the ability to complete all trial procedures; * Age 18-80 years at time of signing informed consent (including threshold); * ECOG score 0 or 1; * No previous surgery for lung cancer; * Intraoperative or postoperative pathologically confirmed non-small cell lung cancer; * Single pulmonary nodule with mixed ground glass on CT, or multiple pulmonary nodules but the main lesion is the above nodules; * The proportion of solid components of the nodule is between 0.5 and 1, and the total size of the nodule is less than or equal to 2 cm; * Patients with clinical stage T1N0M0 surgically resectable; * Primary treatment without radiotherapy or chemotherapy. Exclusion Criteria: * T1N0M0 with a clinical stage other than 0.5 \< CTR \< 1 and a diameter of ≤ 2 cm; * Inability to perform complete surgical resection; * cytology or histopathology confirms that it is a lung malignant tumor other than non-small cell lung cancer; * Previous surgery for lung cancer; * Patients who have received radiotherapy or chemotherapy for non-primary treatment.
References
Publications (0)
Data not yet available